spacer
home > epc > autumn 2017 > ethical approaches
PUBLICATIONS
European Pharmaceutical Contractor

Ethical Approaches

Despite the continuous development of new treatments, availability of efficient and safe methods remains a great unmet need. This term, ‘methods’, refers to the vast range of approaches to chemical and biologic medications, cell-based therapies, medical devices, psychotherapy and so on. Testing new procedures against placebo is thought to provide the most reliable data on the value of a new solution.

However, it is not unusual that this comparison is unfeasible for technical or practical reasons or because it is considered unethical. The latter especially affects the development of treatments for severe diseases or for vulnerable populations, where the use of a placebo instead of an active comparator or standard-of-care may be dangerous for the subject. In some cases, the use of placebos can also be linked with a risk to other people, for example, due to an increased possibility of aggressive or asocial behaviours.

These considerations have fuelled many years of debate over the use of placebos in clinical trials. Regulators, opinion leaders, patient advocates and journalists express their opinions on this matter – noticing a disagreement between the stakeholders is easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Piotr Piotrowski is a Medical Director at KCR and holds a PhD in neurology. He is responsible for cross-therapeutic oversight of new and ongoing company projects from a medical perspective. Piotr’s professional experience includes more than 10 years in medical affairs, preclinical research, clinical development and regulatory affairs in the environment of the world’s top pharma industry and academic entities.

Dr Magdalena Czarnecka is a member of the Commercial Project Support Team at KCR, responsible for landscaping and development of clinical documentation. She gathered her professional experience during preclinical research at Georgetown University in Washington DC, US, and her work for a consulting firm focused on medical technology assessment. Magdalena holds a PhD in physiology and biophysics.

Dr Anna Baran
is a Chief Medical Officer at KCR. She leads the organisation’s early stages of study operations and provides cross-functional support to all service areas, ensuring the smooth integration of medical affairs and regulatory and business development efforts. Throughout her career, Anna has worked closely with recognised authorities across Eastern Europe and has been involved in developing national legislation for clinical trials registration.
spacer
Dr Piotr Piotrowsk
spacer
spacer
spacer
Dr Magdalena Czarnecka
spacer
spacer
spacer
Dr Anna Baran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

PPMA SHOW 2018

25-27 September 2018, NEC, Birmingham, UK

The UK’s leading production line event is celebrating its 30th Anniversary. Taking place at the NEC, Birmingham from 25-27 September 2018, the exhibition showcases the latest processing and packaging machinery. Attended by thousands of manufacturers of food, pharmaceuticals and FMCG as well as contract packers and more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement